Article
Medicine, Research & Experimental
Erika S. Varady, L. Angel Ayala, Pauline U. Nguyen, Vanessa M. Scarfone, Alborz Karimzadeh, Cuiwen Zhou, Xiyu Chen, Scott A. Greilach, Craig M. Walsh, Matthew A. Inlay
Summary: Donor cell conditioning with the glucocorticoid fluticasone propionate (FLU) prior to transplantation increases HSC engraftment and reduces the severity and incidence of graft-versus-host disease (GvHD) in allogeneic hosts.
EMBO MOLECULAR MEDICINE
(2023)
Article
Oncology
Jose Carlos Jaime-Perez, Ernesto Picon-Galindo, Jose Luis Herrera-Garza, David Gomez-Almaguer
Summary: The study analyzed outpatient second allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning after autografting or allografting failure or relapse. Data comparison indicated that chronic graft-versus-host disease and late second transplantation were protective factors for longer survival.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Hematology
Patrizia Chiusolo, Stefania Bregante, Sabrina Giammarco, Teresa Lamparelli, Lucia Casarino, Alida Dominietto, Anna Maria Raiola, Elisabetta Metafuni, Carmen Di Grazia, Francesca Gualandi, Federica Sora, Luca Laurenti, Simona Sica, Gianni Barosi, Fabio Guolo, Monica Rossi, Elena Rossi, Alessandro Vannucchi, Alessio Signori, Valerio De Stefano, Andrea Bacigalupo, Emanuele Angelucci
Summary: The combination of two alkylating agents in conditioning regimen for patients with myelofibrosis undergoing allogeneic HSCT leads to a higher rate of achieving full donor chimerism on day +30, resulting in better long term disease-free survival.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Review
Immunology
Asim Saha, Bruce R. Blazar
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment option for hematological malignancies. However, conventional allo-HSCT methods have adverse effects and can lead to graft-versus-host-disease. Recent developments in targeted radiotherapy and antibody-based conditioning show promise in improving the outcomes of allo-HSCT.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biophysics
Shun Koyamaishi, Takuya Kamio, Akie Kobayashi, Tomohiko Sato, Ko Kudo, Shinya Sasaki, Rika Kanezaki, Daiichiro Hasegawa, Hideki Muramatsu, Yoshiyuki Takahashi, Yoji Sasahara, Hidefumi Hiramatsu, Harumi Kakuda, Miyuki Tanaka, Masataka Ishimura, Masanori Nishi, Akira Ishiguro, Hiromasa Yabe, Takeo Sarashina, Masaki Yamamoto, Yuki Yuza, Nobuyuki Hyakuna, Kenichi Yoshida, Hitoshi Kanno, Shouichi Ohga, Akira Ohara, Seiji Kojima, Satoru Miyano, Seishi Ogawa, Tsutomu Toki, Kiminori Terui, Etsuro Ito
Summary: This study retrospectively compared the outcomes of DBA patients undergoing HSCT with MAC or RIC conditioning regimens. All 27 patients who underwent HSCT successfully engrafted, with a 3-year overall survival rate of 95.2% and a failure-free survival rate of 88.4%, showing no significant differences between MAC and RIC regimens.
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Suguru Uemura, Daiichiro Hasegawa, Kenji Kishimoto, Tomoko Fujikawa, Sayaka Nakamura, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Takeshi Mori, Kayo Ozaki, Yoshiyuki Kosaka
Summary: This study examined the association between conditioning intensity and height growth in pediatric patients who underwent allo-HSCT. The results showed significant differences in height SDS between MAC and RIC groups at 2 and 3 years after allo-HSCT. Multivariate logistic regression analysis indicated that MAC regimen was associated with an increased risk of short stature at 3 years after allo-HSCT.
Article
Hematology
Oscar B. Lahoud, Sean M. Devlin, Molly A. Maloy, Lindsey E. Roeker, Parastoo B. Dahi, Doris M. Ponce, Boglarka Gyurkocza, Guenther Koehne, James W. Young, Hugo R. Castro-Malaspina, Juliet N. Barker, Esperanza B. Papadopoulos, Ann A. Jakubowski, Andrew D. Zelenetz, Anthony R. Mato, Sergio A. Giralt, Miguel A. Perales, Craig S. Sauter
Summary: This study demonstrates that allogeneic hematopoietic stem cell transplantation (HSCT) can potentially cure patients with chronic lymphocytic leukemia (CLL), with favorable progression-free survival (PFS) and overall survival (OS) rates. The impact of novel agents on HSCT outcomes was found to be negligible. Reduced intensity conditioning (RIC) HSCT may be a successful treatment option for CLL patients with Richter's transformation and poor-risk CLL patients.
Article
Biophysics
Alexandros Spyridonidis, Myriam Labopin, Tobias Gedde-Dahl, Arnold Ganser, Matthias Stelljes, Charles Craddock, Eva Maria Wagner-Drouet, Jurjen Versluis, Thomas Schroeder, Igor Wolfgang Blau, Gerald. G. Wulf, Peter Dreger, Gitte Olesen, Henrik Sengeloev, Nicolaus Kroger, Victoria Potter, Edouard Forcade, Jakob Passweg, Regis Peffault de Latour, Johan Maertens, Keith M. O. Wilson, Jean Henri Bourhis, Juergen Finke, Eolia Brissot, Ali Bazarbachi, Sebastian Giebel, Bipin P. Savani, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: This study confirms the effectiveness of the recently developed transplant conditioning intensity (TCI) score in predicting mortality and relapse rates in hematopoietic cell transplantation.
BONE MARROW TRANSPLANTATION
(2023)
Review
Gastroenterology & Hepatology
Quentin Le Bastard, Patrice Chevallier, Emmanuel Montassier
Summary: Allogeneic hematopoietic stem cell transplantation is a validated therapy for hematological diseases, but can be limited by life-threatening complications like acute GVHD. Recent research on the relationship between gut microbiome changes and acute GVHD in aHSCT recipients suggests potential implications for diagnosis, prevention, and therapy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Medical Laboratory Technology
Ivan Pasic, Annie H. Ren, Ram Vasudevan Nampoothiri, Ioannis Prassas, Jeffrey H. Lipton, Jonas Mattsson, Eleftherios P. Diamandis, Fotios V. Michelis
Summary: Using a novel multiplex antibody-based proximity extension assay, researchers identified serum proteins, including SLAMF7, IL-1ra, BTN3A2, and DAB2, that may potentially serve as biomarkers for acute graft-vs.-host disease.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Immunology
Agnieszka Tomaszewska, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, Peter Remenyi, Fabio Ciceri, Jean H. Bourhis, Patrice Chevallier, Carlos Solano, Gerard Socie, Benedetto Bruno, Alessandro Rambaldi, Luca Castagna, Nicolaus Kroger, Paolo Corradini, Boris Afanasyev, Marco Ladetto, Dietger Niederwieser, Christof Scheid, Henrik Sengeloev, Frank Kroschinsky, Ibrahim Yakoub-Agha, Helene Schoemans, Christian Koenecke, Olaf Penack, Zinaida Peric, Hildegard Greinix, Rafael F. Duarte, Grzegorz W. Basak
Summary: A retrospective analysis of 3839 adult patients with B-cell malignancies undergoing alloHCT found that adding rituximab to reduced intensity conditioning regimens did not significantly impact major transplant outcome variables. However, the lack of data on chronic GVHD in this study limits the conclusions that can be drawn.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Shlomo Elias, Samantha Brown, Sean M. Devlin, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Oscar B. Lahoud, Heather Landau, Richard J. Lin, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, James W. Young, Miguel-Angel Perales, Roni Shouval
Summary: Comorbidity assessment is important before allogeneic haematopoietic cell transplantation (allo-HCT) to estimate non-relapse mortality (NRM) risk. The Simplified Comorbidity Index (SCI), which includes a small number of comorbidities and older age, has been shown to predict NRM. In this study, we validated the SCI in patients receiving reduced-intensity conditioning followed by allo-HCT from HLA-matched donors. Higher SCI scores were associated with increased NRM risk and reduced overall survival. These findings suggest that the SCI is a reliable tool for risk stratification in allo-HCT candidates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biophysics
Kaito Harada, Shun-ichi Kimura, Shigeo Fuji, Yuho Najima, Kimikazu Yakushijin, Naoyuki Uchida, Makoto Onizuka, Kazuhiro Ikegame, Shingo Yano, Naoki Shingai, Ken-ichi Matsuoka, Yasushi Onishi, Masashi Sawa, Satoru Takada, Toshiro Kawakita, Takahiro Fukuda, Junya Kanda, Yoshiko Atsuta, Hideaki Nakasone
Summary: A comprehensive scoring system was developed to assess mortality risk after salvage stem cell transplant for graft failure, stratifying patients into different survival rate groups to provide a useful predictive tool for clinical outcomes.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Ning Wu, Ruoyang Liu, Shuang Liang, Haitao Gao, Lan-Ping Xu, Xiao-Hui Zhang, Jiangying Liu, Xiao-Jun Huang
Summary: In the development of aGVHD, gamma delta T cells were found to indirectly regulate the migration of CD4 T cells to target tissues, rather than directly triggering alloreactive responses. This study suggests a potential role for gamma delta T cells in recruiting alloreactive CD4 T cells through the expression of CXCR4, providing new insights into the mechanism of aGVHD and potential therapeutic targets.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Naveed Ali, Ashish Arunkumar Sharma, Ana Carolina Pires de Rezende, Folashade Otegbeye, Bilal Muhammad Latif, Mariana Nassif Kerbauy, Brenda W. Cooper, Gabriela Sanchez, Leland Metheny, Saswat K. Bal, Roberto Sakuraba, Benjamin K. Tomlinson, Kirsten M. Boughan, Lucila Kerbauy, Ehsan Malek, Andreza Feitosa Ribeiro, Molly Gallogly, David Mansur, Gisele Pereira, Eduardo Weltman, Rafick-Pierre Sekaly, Marcos de Lima, Paolo F. Caimi, Nelson Hamerschlak
Summary: This study evaluated the efficacy of intensified fludarabine/busulfan (Flu/Bu) reduced-intensity conditioning (RIC) regimen with targeted marrow irradiation (TMI) in high-risk hematologic malignancies patients. The results showed that this approach was feasible with low transplantation-related mortality in medically frail patients with advanced malignancies.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)